(
Microbicide Trials Network) A vaginal ring designed to protect women against both HIV and herpes simplex virus type 2 (HSV-2) is being tested in a new study that aims to determine whether its use for three months is safe. The Phase I study, taking place at three U.S. trial sites, is one of two studies evaluating full 90-day use of the ring, which contains an antiretroviral drug called tenofovir, and the first to enroll participants.
